Valneva: new study on the anti-chikungunya vaccine

(CercleFinance.com) – Valneva announces that it has initiated a study to assess the homogeneity of phase III clinical batches of its single-injection vaccine candidate against chikungunya, VLA1553. Study volunteers will be followed for a total of six months.

The objective is to demonstrate the homogeneity of the manufacture of the vaccine by showing that three consecutively manufactured batches elicit equivalent immune responses by measuring the titers of neutralizing antibodies 29 days after vaccination.

The biotechnology company specifies that this study will be conducted in parallel with the pivotal phase III study already underway, VLA1553-301, which relates in particular to the determination of seroprotection on the basis of immunological criteria.

.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.